UDP-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer

Dali Huang, George P Casale, Jun Tian, Subodh M Lele, Vladimir M. Pisarev, Melanie A. Simpson, George P. Hemstreet

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Uridine diphosphate (UDP)-glucose dehydrogenase (UGDH) catalyzes the oxidation of UDP-glucose to yield UDP-glucuronic acid, a precursor for synthesis of glycosaminoglycans and proteoglycans that promote aggressive prostate cancer (PC) progression. The purpose of our study was to determine if the UGDH expression in normal appearing acini (NAA) from cancerous glands is a candidate biomarker for PC field disease/effect assayed by quantitative fluorescence imaging analysis (QFIA). A polyclonal antibody to UGDH was titrated to saturation binding and fluorescent microscopic images acquired from fixed, paraffin-embedded tissue slices were quantitatively analyzed. Specificity of the assay was confirmed by Western blot analysis and competitive inhibition of tissue labeling with the recombinant UGDH. Reproducibility of the UGDH measurements was high within and across analytical runs. Quantification of UGDH by QFIA and Reverse-Phase Protein Array analysis were strongly correlated (r 5 0.97), validating the QFIA measurements. Analysis of cancerous acini (CA) and NAA from PC patients vs. normal acini (NA) from noncancerous controls (32 matched pairs) revealed significant (p < 0.01) differences, with CA (increased) vs. NA, NAA (decreased) vs. NA and CA (increased) vs. NAA. Areas under the Receiver Operating Characteristic curves were 0.68 (95% CI: 0.59-0.83) for NAA and 0.71 (95% CI: 0.59-0.83) for CA (both vs. NA). These results support the UGDH content in prostatic acini as a novel candidate biomarker that may complement the development of a multi-biomarker panel for detecting PC within the tumor adjacent field on a histologically normal biopsy specimen.

Original languageEnglish (US)
Pages (from-to)315-327
Number of pages13
JournalInternational Journal of Cancer
Volume126
Issue number2
DOIs
StatePublished - Jan 15 2010

Fingerprint

Uridine Diphosphate Glucose Dehydrogenase
Prostatic Neoplasms
Biomarkers
Optical Imaging
Uridine Diphosphate Glucuronic Acid
Uridine Diphosphate Glucose
Protein Array Analysis
Proteoglycans
Glycosaminoglycans
ROC Curve
Paraffin
Western Blotting
Biopsy
Antibodies

Keywords

  • Biomarker
  • Field disease/effect
  • Prostate cancer
  • Tissue proteomics
  • UGDH

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

UDP-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer. / Huang, Dali; Casale, George P; Tian, Jun; Lele, Subodh M; Pisarev, Vladimir M.; Simpson, Melanie A.; Hemstreet, George P.

In: International Journal of Cancer, Vol. 126, No. 2, 15.01.2010, p. 315-327.

Research output: Contribution to journalArticle

Huang, Dali ; Casale, George P ; Tian, Jun ; Lele, Subodh M ; Pisarev, Vladimir M. ; Simpson, Melanie A. ; Hemstreet, George P. / UDP-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer. In: International Journal of Cancer. 2010 ; Vol. 126, No. 2. pp. 315-327.
@article{7c61bba195f14fcd97a43dd0895d7b9f,
title = "UDP-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer",
abstract = "Uridine diphosphate (UDP)-glucose dehydrogenase (UGDH) catalyzes the oxidation of UDP-glucose to yield UDP-glucuronic acid, a precursor for synthesis of glycosaminoglycans and proteoglycans that promote aggressive prostate cancer (PC) progression. The purpose of our study was to determine if the UGDH expression in normal appearing acini (NAA) from cancerous glands is a candidate biomarker for PC field disease/effect assayed by quantitative fluorescence imaging analysis (QFIA). A polyclonal antibody to UGDH was titrated to saturation binding and fluorescent microscopic images acquired from fixed, paraffin-embedded tissue slices were quantitatively analyzed. Specificity of the assay was confirmed by Western blot analysis and competitive inhibition of tissue labeling with the recombinant UGDH. Reproducibility of the UGDH measurements was high within and across analytical runs. Quantification of UGDH by QFIA and Reverse-Phase Protein Array analysis were strongly correlated (r 5 0.97), validating the QFIA measurements. Analysis of cancerous acini (CA) and NAA from PC patients vs. normal acini (NA) from noncancerous controls (32 matched pairs) revealed significant (p < 0.01) differences, with CA (increased) vs. NA, NAA (decreased) vs. NA and CA (increased) vs. NAA. Areas under the Receiver Operating Characteristic curves were 0.68 (95{\%} CI: 0.59-0.83) for NAA and 0.71 (95{\%} CI: 0.59-0.83) for CA (both vs. NA). These results support the UGDH content in prostatic acini as a novel candidate biomarker that may complement the development of a multi-biomarker panel for detecting PC within the tumor adjacent field on a histologically normal biopsy specimen.",
keywords = "Biomarker, Field disease/effect, Prostate cancer, Tissue proteomics, UGDH",
author = "Dali Huang and Casale, {George P} and Jun Tian and Lele, {Subodh M} and Pisarev, {Vladimir M.} and Simpson, {Melanie A.} and Hemstreet, {George P.}",
year = "2010",
month = "1",
day = "15",
doi = "10.1002/ijc.24820",
language = "English (US)",
volume = "126",
pages = "315--327",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - UDP-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer

AU - Huang, Dali

AU - Casale, George P

AU - Tian, Jun

AU - Lele, Subodh M

AU - Pisarev, Vladimir M.

AU - Simpson, Melanie A.

AU - Hemstreet, George P.

PY - 2010/1/15

Y1 - 2010/1/15

N2 - Uridine diphosphate (UDP)-glucose dehydrogenase (UGDH) catalyzes the oxidation of UDP-glucose to yield UDP-glucuronic acid, a precursor for synthesis of glycosaminoglycans and proteoglycans that promote aggressive prostate cancer (PC) progression. The purpose of our study was to determine if the UGDH expression in normal appearing acini (NAA) from cancerous glands is a candidate biomarker for PC field disease/effect assayed by quantitative fluorescence imaging analysis (QFIA). A polyclonal antibody to UGDH was titrated to saturation binding and fluorescent microscopic images acquired from fixed, paraffin-embedded tissue slices were quantitatively analyzed. Specificity of the assay was confirmed by Western blot analysis and competitive inhibition of tissue labeling with the recombinant UGDH. Reproducibility of the UGDH measurements was high within and across analytical runs. Quantification of UGDH by QFIA and Reverse-Phase Protein Array analysis were strongly correlated (r 5 0.97), validating the QFIA measurements. Analysis of cancerous acini (CA) and NAA from PC patients vs. normal acini (NA) from noncancerous controls (32 matched pairs) revealed significant (p < 0.01) differences, with CA (increased) vs. NA, NAA (decreased) vs. NA and CA (increased) vs. NAA. Areas under the Receiver Operating Characteristic curves were 0.68 (95% CI: 0.59-0.83) for NAA and 0.71 (95% CI: 0.59-0.83) for CA (both vs. NA). These results support the UGDH content in prostatic acini as a novel candidate biomarker that may complement the development of a multi-biomarker panel for detecting PC within the tumor adjacent field on a histologically normal biopsy specimen.

AB - Uridine diphosphate (UDP)-glucose dehydrogenase (UGDH) catalyzes the oxidation of UDP-glucose to yield UDP-glucuronic acid, a precursor for synthesis of glycosaminoglycans and proteoglycans that promote aggressive prostate cancer (PC) progression. The purpose of our study was to determine if the UGDH expression in normal appearing acini (NAA) from cancerous glands is a candidate biomarker for PC field disease/effect assayed by quantitative fluorescence imaging analysis (QFIA). A polyclonal antibody to UGDH was titrated to saturation binding and fluorescent microscopic images acquired from fixed, paraffin-embedded tissue slices were quantitatively analyzed. Specificity of the assay was confirmed by Western blot analysis and competitive inhibition of tissue labeling with the recombinant UGDH. Reproducibility of the UGDH measurements was high within and across analytical runs. Quantification of UGDH by QFIA and Reverse-Phase Protein Array analysis were strongly correlated (r 5 0.97), validating the QFIA measurements. Analysis of cancerous acini (CA) and NAA from PC patients vs. normal acini (NA) from noncancerous controls (32 matched pairs) revealed significant (p < 0.01) differences, with CA (increased) vs. NA, NAA (decreased) vs. NA and CA (increased) vs. NAA. Areas under the Receiver Operating Characteristic curves were 0.68 (95% CI: 0.59-0.83) for NAA and 0.71 (95% CI: 0.59-0.83) for CA (both vs. NA). These results support the UGDH content in prostatic acini as a novel candidate biomarker that may complement the development of a multi-biomarker panel for detecting PC within the tumor adjacent field on a histologically normal biopsy specimen.

KW - Biomarker

KW - Field disease/effect

KW - Prostate cancer

KW - Tissue proteomics

KW - UGDH

UR - http://www.scopus.com/inward/record.url?scp=73549102171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73549102171&partnerID=8YFLogxK

U2 - 10.1002/ijc.24820

DO - 10.1002/ijc.24820

M3 - Article

C2 - 19676054

AN - SCOPUS:73549102171

VL - 126

SP - 315

EP - 327

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -